THER has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
THER has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gross Margin % is calculated as gross profit divided by its revenue. Theralink Technologies's Gross Profit for the three months ended in Dec. 2023 was $0.03 Mil. Theralink Technologies's Revenue for the three months ended in Dec. 2023 was $0.08 Mil. Therefore, Theralink Technologies's Gross Margin % for the quarter that ended in Dec. 2023 was 36.90%.
The historical rank and industry rank for Theralink Technologies's Gross Margin % or its related term are showing as below:
Theralink Technologies had a gross margin of 36.90% for the quarter that ended in Dec. 2023 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Theralink Technologies was 0.00% per year.
The historical data trend for Theralink Technologies's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralink Technologies Annual Data | |||||||||||||||||||||
Trend | Feb14 | Feb15 | Dec16 | Dec17 | Dec18 | Dec19 | Sep20 | Sep21 | Sep22 | Sep23 | |||||||||||
Gross Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
- | 71.27 | 76.68 | 60.39 | 79.24 |
Theralink Technologies Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Gross Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
80.00 | 84.71 | 75.25 | 77.65 | 36.90 |
For the Biotechnology subindustry, Theralink Technologies's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Theralink Technologies's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Theralink Technologies's Gross Margin % falls into.
Gross Margin is the percentage of Gross Profit out of sales or Revenue.
Theralink Technologies's Gross Margin for the fiscal year that ended in Sep. 2023 is calculated as
Gross Margin % (A: Sep. 2023 ) | = | Gross Profit (A: Sep. 2023 ) | / | Revenue (A: Sep. 2023 ) |
= | 0.5 | / | 0.607 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (0.607 - 0.126) | / | 0.607 | |
= | 79.24 % |
Theralink Technologies's Gross Margin for the quarter that ended in Dec. 2023 is calculated as
Gross Margin % (Q: Dec. 2023 ) | = | Gross Profit (Q: Dec. 2023 ) | / | Revenue (Q: Dec. 2023 ) |
= | 0 | / | 0.084 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (0.084 - 0.053) | / | 0.084 | |
= | 36.90 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Theralink Technologies (OTCPK:THER) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Theralink Technologies had a gross margin of 36.90% for the quarter that ended in Dec. 2023 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Thank you for viewing the detailed overview of Theralink Technologies's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Danica Holley | director | 7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814 |
Matthew Wilson Schwartz | director | 15000 W. 6TH AVENUE, SUITE 400, GOLDEN CO 80401 |
Chilcott, Iii Thomas E. | officer: Chief Financial Officer | 373 INVERNESS PARKWAY, ENGLEWOOD CO 80122 |
Jeffrey Busch | director | 7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814 |
Yvonne Fors | director | 1201 MONSTER RD SW STE 350, RENTON WA 98057 |
Michael I Ruxin | director, officer: Chief Executive Officer | HAEMONETICS CORPORATION INCORPORATED, 400 WOOD ROAD, BRAINTREE MA 02184 |
Avant Diagnostics, Inc | 10 percent owner | 1050 30TH STREET NW, SUITE 107, WASHINGTON DC 20007 |
Brian Gill Barnett | officer: Chief Executive Officer | 230 N SPRINGER, LOS ALTOS CA 94024 |
Robert Neal Holcomb | director | PO BOX 535, ROLLING FORK MS 39159 |
Volnie Carlos Fernando Alaman | 10 percent owner, officer: Chief Operating Officer-Vitel | MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000 |
Odabachian Manuel Cosme | director, 10 percent owner, officer: Global Operations GM-Vitel | MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000 |
Daniel S. Hoverman | director | C/O ONCBIOMUNE PHARMACEUTICALS INC.,, 11441 INDUSTRIPLEX BLVD, SUITE 190, BATON ROUGE LA 70809 |
Rice Charles L Jr | director | C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113 |
Andrew Albert Kucharchuk | director, officer: CFO & President | 549 MILGATE PLACE, BATON ROUGE LA 70810 |
Jonathan Frederick Head | director, officer: Chief Executive Officer | 6144 HAGERSTOWN DRIVE, BATON ROUGE LA 70817 |
From GuruFocus
By Marketwired • 11-03-2023
By PRNewswire PRNewswire • 02-22-2021
By PRNewswire PRNewswire • 11-28-2022
By PRNewswire PRNewswire • 04-19-2022
By PRNewswire PRNewswire • 01-17-2023
By Marketwired • 10-04-2023
By PRNewswire PRNewswire • 06-15-2022
By PRNewswire PRNewswire • 09-29-2020
By PRNewswire PRNewswire • 07-05-2022
By PRNewswire PRNewswire • 06-25-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.